<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04931160</url>
  </required_header>
  <id_info>
    <org_study_id>BRAISE DiaPSS</org_study_id>
    <nct_id>NCT04931160</nct_id>
  </id_info>
  <brief_title>B-dependant Rare AutoImmune diseaSES - Cohort of Patients With Suspected Diagnosis of Primitive Sjögren Syndrome</brief_title>
  <acronym>BRAISES-DiaPSS</acronym>
  <official_title>B-dependant Rare AutoImmune diseaSES - Cohort of Patients With Suspected Diagnosis of Primitive Sjögren Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectif is to study the diagnosis performance of the different classification criteria&#xD;
      in reference to the gold standard consisting of the diagnosis made by expert doctors after&#xD;
      standardized assessment, of pSS (primary Sjogren syndrome)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The formation of this patient is single-center prospective intervention. It consists of&#xD;
      collecting data from patients suspected of pSS from standardized biological clinical data and&#xD;
      imaging examination and additional pathology.&#xD;
&#xD;
        -  Sjögren patients will be followed at inclusion, 2y, 3y, 4y, 6y, 8y and 10 years. Blood,&#xD;
           fluid, sells and urine samples will be collected at inclusion, 4y et 10y.&#xD;
&#xD;
        -  Non-Sjögren controls will be followed at inclusion and 4y and samples will be collected&#xD;
           at the same visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2020</start_date>
  <completion_date type="Anticipated">February 10, 2035</completion_date>
  <primary_completion_date type="Anticipated">February 10, 2035</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Sjögren patients&#xD;
Non-Sjögren controls (retrospective)</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Description specificity of different classification criteria FOR sJOGREN (EULAR/ACR 2019, european criteria)</measure>
    <time_frame>Inclusion</time_frame>
    <description>Specificity of different classification criteria, the standard gold being the diagnosis obtained by consensus of expert doctors after standardized assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with different manifestation including in the ESSDAI (Eular Sjögren Syndrome Disease Activity index), gold standard to measure</measure>
    <time_frame>10 years</time_frame>
    <description>number of patients wit arthritis of more than 6 joints, parotidomegaly, intertitial lung disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with rheumatological manifestations</measure>
    <time_frame>10 years</time_frame>
    <description>number of patients wit arthritis of more than 6 joints, parotidomegaly, intertitial lung disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with dermatological manifestations</measure>
    <time_frame>10 years</time_frame>
    <description>number of patients wit arthritis of more than 6 joints, parotidomegaly, intertitial lung disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description diagnostic performance of new tests</measure>
    <time_frame>10 years</time_frame>
    <description>after evaluation of all différents test performed added to the classical items of the ACR 2017: ie ultrasound parenchymal abnormalities, sub population of B cells....</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease evolution criteria</measure>
    <time_frame>10 years</time_frame>
    <description>modification of the ESSDAI at each visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Sjogren's Syndrome</condition>
  <arm_group>
    <arm_group_label>Sjögren patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients diagnosed Sjögren</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Sjögren witnesses</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients diagnosed no Sjögren</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood, fluid, sells and urine samples</intervention_name>
    <description>Blood, fluid, sells and urine samples will be collected.</description>
    <arm_group_label>Non-Sjögren witnesses</arm_group_label>
    <arm_group_label>Sjögren patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Major patient&#xD;
&#xD;
          -  Suspicion of SSp (clinical or biological criteria, i.e. dry eye or oral syndrome,&#xD;
             arthritis, parotidomegaly, neuropathy, kidney or lung disease...)&#xD;
&#xD;
          -  Patient affiliated with Social Security&#xD;
&#xD;
          -  Patient who has signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to participate&#xD;
&#xD;
          -  Pregnant and lactating woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valérie Devauchelle</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Brest</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valérie Devauchelle, MD,PhD</last_name>
    <phone>33 (0) 2 98 34 72 64</phone>
    <email>valerie.devauchelle-pensec@chu-brest.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie DEVAUCHELLE</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 23, 2019</study_first_submitted>
  <study_first_submitted_qc>June 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

